The shorters have won again

It's Phil King against the shorters at small-cap biotechnology play Opthea, which counts the veteran stockpicker's Regal Partners as its biggest investor and is preparing to release the results of a crucial clinical trial. But while Regal, with its 30 per cent stake, is long on Opthea, there are plenty who are not.

—//—

can’t imagine Phil will let it go down to zero

it’s now obvious the market was telling this result for a couple of months

With speculation … we can’t expect to win all the time